Oncotab, Inc.
Waxhaw, NC
- UEI
- E5FXNY7GG5M5
- CAGE
- 675Y3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 804 Wandering Way Dr, Waxhaw, NC 28173, USA
- Website
- oncotab.com
- Founded
- 2011
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of targeted radionuclide therapy using tumor specific antibody for triple negative breast cancer | National Cancer Institute (NIH) | $300,000 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Leukogene Therapeutics Inc. | Mount Pleasant, SC | — |
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Deep Creek Pharma LLC | Yadkinville, NC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Viewpoint Molecular Targeting, Inc. | Coralville, IA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Nanocan Therapeutics Corporation | Forest Heights, MD | 541713 Research and Development in Nanotechnology |
About the company
Oncotab, Inc. is a corporate entity registered in SAM.gov since November 2010, located in Waxhaw, North Carolina, that specializes in advanced medical research focusing on cancer diagnostics and therapeutic technologies. The company appears to be primarily engaged in developing innovative cancer research strategies, with a specific emphasis on pancreatic cancer detection and treatment methodologies. While the company has not been awarded federal contract vehicles, it has received multiple significant federal grants from the National Cancer Institute to support its research initiatives.
The federal grant awards received by Oncotab, Inc. demonstrate a concentrated effort in pancreatic cancer research, specifically developing novel diagnostic and therapeutic approaches. The company has secured three notable grants from the National Cancer Institute, each addressing different aspects of pancreatic ductal adenocarcinoma (PDAC) research. These grants include developing an optimized targeted radiotherapy using tumor-specific antibodies, creating bispecific antibodies for cancer immunotherapy, and designing an integrated strategy for early pancreatic cancer detection using serum and imaging biomarkers. The research involves sophisticated techniques such as developing humanized antibodies (HTAB004), creating bispecific antibodies that target tumor-associated MUC1 (TMUC1), and designing innovative screening methods like the Agkura Personal Score (APS) test. Collaborations with entities like DualLogics LLC and research institutions such as the University of North Carolina at Charlotte have been integral to these research efforts, demonstrating Oncotab's commitment to advancing pancreatic cancer research through cutting-edge scientific approaches.
SBA capabilities narrative
CLIA Laboratory; Biotech R&D
Quick answers
Is Oncotab, Inc. registered in SAM.gov?
Oncotab, Inc.'s SAM.gov registration expired on October 25, 2026.
What is Oncotab, Inc.'s most recent federal award?
Oncotab, Inc.'s most recent federal grant award is Combination therapy of t-cell engager and chemotherapy for pancreatic cancer treatment - the american cancer society… (R44CA306447), from National Cancer Institute (NIH), on August 1, 2026.
On GovTribe
See Oncotab, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors